Provectus (PVCT) director granted Series D-1 convertible preferred stock

Rhea-AI Filing Summary

Provectus Biopharmaceuticals director Bailey Webster received a grant of 48,917 shares of Series D-1 Convertible Preferred Stock. The shares were acquired on June 30, 2026 at a stated price of $0.00 per share as a grant or award, not an open-market transaction.

Each share of Series D-1 Preferred Stock is convertible into 10 shares of Provectus common stock. The Series D-1 Preferred Stock will automatically convert into common stock on December 31, 2028, unless converted earlier under the terms of its Certificate of Designation. Following this grant, Webster directly holds 207,535 shares of Series D-1 Preferred Stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bailey Webster

Role null

Type	Security	Shares	Price	Value
Grant/Award	Series D-1 Convertible Preferred Stock	48,917	$0.00	--

Holdings After Transaction: Series D-1 Convertible Preferred Stock — 207,535 shares (Direct, null)

Footnotes (1)

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

Key Figures

Preferred shares granted: 48,917 shares Grant price per share: $0.00 per share Underlying common shares: 489,170 shares +3 more

6 metrics

Preferred shares granted 48,917 shares Series D-1 Convertible Preferred Stock granted on June 30, 2026

Grant price per share $0.00 per share Series D-1 Convertible Preferred Stock award

Underlying common shares 489,170 shares Common stock underlying the 48,917 preferred shares

Total preferred holdings after grant 207,535 shares Series D-1 Convertible Preferred Stock held directly after transaction

Conversion ratio 10 common per preferred share Series D-1 Convertible Preferred Stock terms

Automatic conversion date December 31, 2028 Scheduled automatic conversion of Series D-1 into common stock

Key Terms

Series D-1 Convertible Preferred Stock, automatic convert, Certificate of Designation, par value

4 terms

Series D-1 Convertible Preferred Stock financial

"Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock."

automatic convert financial

"The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028."

Certificate of Designation regulatory

"Converted into Common Stock in accordance with the terms of the Certificate of Designation."

A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.

par value financial

"Common stock, par value $0.001 per share."

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/30/2026 - 09:19 PM Accepted by SEC EDGAR 06/30/2026 - 09:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bailey Webster

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TENNESSEE 37929

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series D-1 Convertible Preferred Stock	(1)	06/30/2026		A		48,917		06/30/2026	(2)	Common Stock	489,170	$0	207,535	D

Explanation of Responses:

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

	/s/ Webster Bailey	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Provectus Biopharmaceuticals (PVCT) disclose for Bailey Webster?

Provectus Biopharmaceuticals reported that director Bailey Webster received a grant of 48,917 shares of Series D-1 Convertible Preferred Stock. The award was recorded on June 30, 2026 at a stated price of $0.00 per share as a grant or other acquisition, not a market trade.

How many Provectus (PVCT) preferred shares does Bailey Webster hold after this Form 4?

After the June 30, 2026 grant, Bailey Webster directly holds 207,535 shares of Provectus Series D-1 Convertible Preferred Stock. This figure represents total holdings of that preferred series reported following the transaction, providing context for the size of the new grant relative to the director’s existing position.

What is the conversion ratio for Provectus (PVCT) Series D-1 Convertible Preferred Stock?

Each share of Provectus Series D-1 Convertible Preferred Stock is convertible into 10 shares of the company’s common stock. This fixed 10-for-1 conversion ratio is specified in the filing and governs how many common shares the preferred stock becomes upon conversion under its terms.

When will Provectus (PVCT) Series D-1 Convertible Preferred Stock automatically convert?

The Series D-1 Convertible Preferred Stock will automatically convert into Provectus common stock on December 31, 2028. It may also be converted earlier into common stock in accordance with the Certificate of Designation terms that govern this preferred series and its conversion mechanics.

Was Bailey Webster’s Provectus (PVCT) preferred stock transaction a purchase or a grant?

The transaction was a grant or award acquisition, coded as “A” on the Form 4. The filing lists 48,917 shares of Series D-1 Convertible Preferred Stock acquired at a stated price of $0.00 per share, indicating a compensation-related award rather than a cash market purchase.